Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1975;45:359-364
© 1975 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PORRECO, R.
Right arrow Articles by MAKOWSKI, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PORRECO, R.
Right arrow Articles by MAKOWSKI, E.

Gynecologic Malignancies in Immunosuppressed Organ Homograft Recipients

RICHARD PORRECO, MD, ISRAEL PENN, MD, WILLIAM DROEGEMUELLER, MD,FACOG, BENJAMIN GREER, MD and EDGAR MAKOWSKI, MD, FACOG

From the Department of Obstetrics and Gynecology, University of Colorado School of Medicine and the Department of Surgery, Veterans Administration Hospital, Denver, Colorado

Abstract

Immunosuppressed organ homograft recipients have a 5 to 69% incidence of de novo malignancies at some time after transplantation. Gynecologic cancers were encountered in 21 of 224 patients (9%) with these tumors. The predominant lesion was carcinoma of the cervix (18 cases), of which 16 were intraepithelial and 2 were invasive. Gynecologic malignancies have also been encountered in non-transplant patients who were treated with immunosuppressive agents or cancer chemotherapy. All such individuals require gynecologic examination before commencement of treatment and at regular intervals thereafter so that malignancies may be diagnosed at an early stage and treated effectively. Most neoplasms respond well to conventional cancer therapy, but high-grade malignancies may necessitate reduction or cessation of immunosuppressive therapy as well.




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
C. N. Kotton and J. A. Fishman
Viral Infection in the Renal Transplant Recipient
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1758 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
J. Am. Soc. Nephrol., October 1, 2000; 11(2007): S1 - S86.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. S. Mandelblatt, P. Kanetsky, L. Eggert, and K. Gold
Is HIV Infection a Cofactor for Cervical Squamous Cell Neoplasia?
Cancer Epidemiol. Biomarkers Prev., January 1, 1999; 8(1): 97 - 106.
[Abstract] [Full Text]

Home page
 The OncologistHome page
H. T. Lynch, M. J. Casey, T. G. Shaw, and J. F. Lynch
Hereditary Factors in Gynecologic Cancer
Oncologist, October 1, 1998; 3(5): 319 - 338.
[Abstract] [Full Text]

Home page
 LupusHome page
Z. Blumenfeld, M. Lorber, N. Yoffe, and Y. Scharf
Systemic Lupus Erythematosus: Predisposition for Uterine Cervical Dysplasia
Lupus, February 1, 1994; 3(1): 59 - 61.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by the American College of Obstetricians and Gynecologists.